FilingReader Intelligence
GNI subsidiary boosts Gyre Pharmaceuticals stake to 70%
August 6, 2025 at 11:59 PM UTC•By FilingReader AI
Gyre Therapeutics acquired an additional 9.18 million shares of Gyre Pharmaceuticals for $1.28 million, raising its stake from 65% to 70%.
The move comes as Gyre Pharmaceuticals prepares to submit its chronic Hepatitis B liver fibrosis treatment F351 for regulatory approval in Q3 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
TSE:2160•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Gni Group publishes news
Free account required • Unsubscribe anytime